Intraplantar β-Caryophyllene Alleviates Pain and Inflammation in STZ-Induced Diabetic Peripheral Neuropathy via CB2 Receptor Activation

Diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes, characterized by mechanical allodynia, neuroinflammation, and oxidative stress. Current treatments offer limited efficacy and are often associated with systemic side effects. Emerging evidence suggests that activation of cannabinoid receptor type 2 (CB<sub>2</sub>) may represent a promising target for managing neuropathic pain and inflammation. This study investigates the therapeutic potential of intraplantar β-Caryophyllene (BCP), a selective CB<sub>2</sub> receptor agonist, administered as a topical intervention in a streptozotocin (STZ)-induced DPN mouse model. Hyperglycemia was induced by STZ injections, and diabetic mice received intraplantar BCP (9, 18, or 27 µg) daily for 21 days. Mechanical allodynia was assessed using von Frey filaments, and levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and oxidative stress markers (MDA, SOD, CAT) were quantified in hind paw tissues. BCP dose-dependently alleviated STZ-induced mechanical allodynia, with the 27 µg dose producing the most pronounced effect (<i>p</i> < 0.001). The anti-allodynic effects of BCP were mediated through CB<sub>2</sub> receptor activation, confirmed by reversal with the CB<sub>2</sub> antagonist AM630 (<i>p</i> < 0.001), while the CB<sub>1</sub> antagonist AM251 had no significant impact. In addition, BCP significantly reduced pro-inflammatory cytokines (<i>p</i> < 0.01) and oxidative stress markers (<i>p</i> < 0.001) while restoring antioxidant enzyme activities (<i>p</i> < 0.05). A control group treated with a clinically available topical analgesic cream containing capsaicin 0.075% exhibited limited efficacy. These findings position topical BCP administration as a novel therapeutic strategy for DPN, offering sustained pain relief and modulation of neuroinflammatory and oxidative pathways with minimal systemic exposure. Further clinical studies are warranted to validate its potential for translation into therapeutic practice.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2025-05-07
DOI
https://doi.org/10.3390/ijms26094430
Citations
3
Primary Topic
Pain Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
3.49

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intraplantar β-Caryophyllene Alleviates Pain and Inflammation in STZ-Induced Diabetic Peripheral Neuropathy via CB2 Receptor Activation

Amina M. Bagher
3 citations
International Journal of Molecular Sciences
Pain Mechanisms and Treatments
3.49
article

Intraplantar β-Caryophyllene Alleviates Pain and Inflammation in STZ-Induced Diabetic Peripheral Neuropathy via CB2 Receptor Activation

Amina M. Bagher
article en
3 citations

Abstract

Diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes, characterized by mechanical allodynia, neuroinflammation, and oxidative stress. Current treatments offer limited efficacy and are often associated with systemic side effects. Emerging evidence suggests that activation of cannabinoid receptor type 2 (CB<sub>2</sub>) may represent a promising target for managing neuropathic pain and inflammation. This study investigates the therapeutic potential of intraplantar β-Caryophyllene (BCP), a selective CB<sub>2</sub> receptor agonist, administered as a topical intervention in a streptozotocin (STZ)-induced DPN mouse model. Hyperglycemia was induced by STZ injections, and diabetic mice received intraplantar BCP (9, 18, or 27 µg) daily for 21 days. Mechanical allodynia was assessed using von Frey filaments, and levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and oxidative stress markers (MDA, SOD, CAT) were quantified in hind paw tissues. BCP dose-dependently alleviated STZ-induced mechanical allodynia, with the 27 µg dose producing the most pronounced effect (<i>p</i> < 0.001). The anti-allodynic effects of BCP were mediated through CB<sub>2</sub> receptor activation, confirmed by reversal with the CB<sub>2</sub> antagonist AM630 (<i>p</i> < 0.001), while the CB<sub>1</sub> antagonist AM251 had no significant impact. In addition, BCP significantly reduced pro-inflammatory cytokines (<i>p</i> < 0.01) and oxidative stress markers (<i>p</i> < 0.001) while restoring antioxidant enzyme activities (<i>p</i> < 0.05). A control group treated with a clinically available topical analgesic cream containing capsaicin 0.075% exhibited limited efficacy. These findings position topical BCP administration as a novel therapeutic strategy for DPN, offering sustained pain relief and modulation of neuroinflammatory and oxidative pathways with minimal systemic exposure. Further clinical studies are warranted to validate its potential for translation into therapeutic practice.

International Journal of Molecular SciencesVol. 26(9)
King Abdulaziz University (SA)
King Abdulaziz University
Good health and well-being
Openalex Percentile: Top 8%
Pain Mechanisms and Treatments
3.49
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.